Alkermes plc $ALKS Shares Sold by Vestcor Inc

Vestcor Inc reduced its position in Alkermes plc (NASDAQ:ALKS) by 29.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 43,140 shares of the company’s stock after selling 18,052 shares during the period. Vestcor Inc’s holdings in Alkermes were worth $1,294,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Royal Bank of Canada increased its position in Alkermes by 117.2% during the first quarter. Royal Bank of Canada now owns 275,526 shares of the company’s stock worth $9,098,000 after buying an additional 148,696 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alkermes in the first quarter valued at approximately $213,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Alkermes by 4.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 482,332 shares of the company’s stock valued at $15,927,000 after acquiring an additional 20,091 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Alkermes by 1.3% during the second quarter. Envestnet Asset Management Inc. now owns 43,658 shares of the company’s stock worth $1,249,000 after acquiring an additional 551 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Alkermes by 2.8% in the 2nd quarter. Bank of Montreal Can now owns 28,856 shares of the company’s stock valued at $826,000 after acquiring an additional 799 shares during the period. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Price Performance

Alkermes stock opened at $27.77 on Thursday. The business has a 50 day simple moving average of $31.60 and a 200-day simple moving average of $30.21. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.32. The stock has a market capitalization of $4.63 billion, a PE ratio of 19.42, a price-to-earnings-growth ratio of 6.92 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to analysts’ expectations of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The business’s quarterly revenue was down 10.6% on a year-over-year basis. During the same quarter last year, the business earned $1.05 earnings per share. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Insider Activity

In related news, Director Shane Cooke sold 61,200 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares of the company’s stock, valued at $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Christian Todd Nichols sold 6,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the sale, the senior vice president owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. The trade was a 5.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 157,434 shares of company stock worth $5,305,794 in the last ninety days. 4.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on ALKS shares. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Truist Financial lifted their price objective on shares of Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Royal Bank Of Canada decreased their target price on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Finally, Wall Street Zen lowered Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.07.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.